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Technical advanceField test of a novel detection device for 
Mycobacterium tuberculosis antigen in cough
Ruth McNerney*1, Beyene A Wondafrash1,2, Kebede Amena2, Ato Tesfaye2, Elaine M McCash3 and Nicol J Murray3
Abstract
Background: Tuberculosis is a highly infectious disease that is spread from person to person by infected aerosols 
emitted by patients with respiratory forms of the disease. We describe a novel device that utilizes immunosensor and 
bio-optical technology to detect M. tuberculosis antigen (Ag85B) in cough and demonstrate its use under field 
conditions during a pilot study in an area of high TB incidence.
Methods: The TB Breathalyzer device (Rapid Biosensor Systems Ltd) was field tested in the outpatient clinic of Adama 
Hospital, Ethiopia. Adults seeking diagnosis for respiratory complaints were tested. Following nebulization with 0.9% 
saline patients were asked to cough into a disposable collection device where cough aerosols were deposited. Devices 
were then inserted into a portable instrument to assess whether antigen was present in the sample. Demographic and 
clinical data were recorded and all patients were subjected to chest radiogram and examination of sputum by Ziehl-
Nielsen microscopy. In the absence of culture treatment decisions were based on smear microscopy, chest x-ray and 
clinical assessment. Breathalyzer testing was undertaken by a separate physician to triage and diagnostic assessment.
Results: Sixty individuals were each subjected to a breathalyzer test. The procedure was well tolerated and for each 
patient the testing was completed in less than 10 min. Positive breath test results were recorded for 29 (48%) patients. 
Of 31 patients with a diagnosis of tuberculosis 23 (74%; 95% CI 55-87) were found positive for antigen in their breath 
and 20 (64%; 95% CI 45-80) were smear positive for acid fast bacilli in their sputum. Six patients provided apparent false 
positive breathalyzer results that did not correlate with a diagnosis of tuberculosis.
Conclusions: We propose that the breathalyzer device described warrants further investigation as a tool for studying 
exhalation of M. tuberculosis. The portability, simplicity of use and speed of the test device suggest it may also find use 
as a tool to aid early identification of infectious cases. We recommend studies be undertaken to determine the 
diagnostic sensitivity and specificity of the device when compared to microbiological and clinical indicators of 
tuberculosis disease.
Background
With an estimated annual incidence of over nine million
cases tuberculosis (TB) is believed to be responsible for
more adult deaths each year than any other single infec-
tious agent [1]. The highest burden of disease is currently
borne by the less developed countries of Africa and Asia
where efforts to control TB are hampered by weak health
systems and in some settings, by the high prevalence of
co-infection with HIV [2]. The recent emergence of multi
drug-resistant stains that cannot be cured with standard
treatment regimens has served to emphasize the urgency
of the situation [3,4]. Control of TB in high burden coun-
tries relies on the detection and treatment of infectious
cases, most usually by testing patients attending a health
clinic that report a cough of at least three weeks duration.
The diagnostic tests available in these settings are sputum
smear microscopy, an insensitive technique requiring a
skilled practitioner and chest radiography, a technique
lacking in specificity as well as sensitivity [5]. World
Health Organization estimates suggest that in 2006 there
were 4 million individuals with undiagnosed tuberculosis.
More effective interventions are required to detect and
treat infectious cases earlier in the transmission chain,
particularly in vulnerable communities with a high preva-
lence of HIV.
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Mycobacterium tuberculosis, the causative agent is
spread from person to person via infected aerosols cre-
ated by patients with respiratory forms of the disease.
Bacilli released into the airways following necrosis and
destruction of lung tissue may be expelled from the lungs
and if released in the form of aerosols may remain air-
borne and available for inhalation and infection of a new
host. Despite being the major mode of transmission there
is little data available regarding the exhalation of M.
tuberculosis. Retrospective study of TB contacts suggests
that most transmission within households occurs prior to
diagnosis and the initiation of treatment [6]. Advanced
cavitary disease and the presence of high numbers of M.
tuberculosis in expectorated sputum is associated with
transmission [7] but it is not known how early in the
infection that patients pose a significant risk of infecting
others. There is little data regarding the aerosolization of
bacilli by individual patients and increased knowledge
regarding shedding of bacteria through the course of a
tuberculosis infection would greatly enhance our under-
standing of transmission dynamics and spread of the dis-
ease. Epidemiological studies suggest there is
considerable variation in infectiousness, with some
patients infecting a large number of contacts whereas
others apparently fail to pass on the disease [8-10]. Previ-
ous attempts to assess airborne transmission have relied
on exposure of guinea pigs to hospitalized TB patients
[11,12]. After a period of living in contact with air from
the ward animals were tuberculin tested, followed by
autopsy and assessment of lesions within the lungs. An
alternative was recently offered by Fennelly and col-
leagues who developed a device for capturing cough gen-
erated aerosols from individual patients [13]. Samples of
'cough' were subjected to culture to assess the numbers of
colony forming units of M. tuberculosis. Results were
obtained in 6 to 10 weeks and showed variation in the
quantities of culturable aerosols produced by individual
patients [13]. Detection of specific nucleic acids following
PCR amplification may provide an alternative means of
detecting M. tuberculosis in aerosols where the DNA can
be extracted from filters used to trap the particles and
results obtained the next day [14]. When applied to air
sampled in a hospital in Taiwan this methodology proved
very sensitive as positive samples were obtained not only
in the vicinity of known tuberculosis patients but in all
parts of the hospital that were tested [15]. Rapid point-of-
care methods of assessing whether an individual is expel-
ling M. tuberculosis in their breath have not previously
been reported. Such a device would greatly facilitate
investigation of individual patients and so enable greater
understanding of the factors influencing TB transmis-
sion.
We describe here a novel device that utilizes immu-
nosensor and bio-optical technology to detect M. tuber-
culosis antigen in the breath of human subjects. The RBS
Breathalyzer system (Rapid Biosensor Systems Ltd, Cam-
bridge, UK) is a fully portable device comprising a dispos-
able plastic collection tube (3.5 × 10 cm) into which the
patient coughs [16]. The collection tube has been
designed to collect aerosols and particles coughed out by
the patient. After coughing an internal concentric
plunger is suppressed to collect sample from the sides of
the tube. A twisting action then distributes sample across
the surface of a coated prism at the base of the tube where
the detection reaction takes place. The prism is coated
with anti-tuberculosis antibodies that are primed with
analogue molecules labeled with a fluorescent dye. The
analogue comprises artificially modified peptide subse-
quences of the T-cell epitope from M. tuberculosis Ag85B
[17]. When native M. tuberculosis Ag85B antigens are
presented they are able to displace the analogue, causing
a change in the fluorescent signal. Changes in fluores-
cence are monitored by inserting the collection tube into
a small battery powered instrument containing a diode
laser and a photo-multiplier tube. The device utilises eva-
nescent wave fluorimetry to assess the amount of antigen
present at the surface of the prism [18]. A digital readout
is provided within minutes and the whole test, including
sample collection may be performed in less than 10 min-
utes.
Following a period of assessment by the test developers
(Rapid Biosensor Systems Ltd) an independent study was
performed in a country with a high prevalence of tuber-
culosis to assess whether the device was able detect TB
antigen in cough of patients when used in the field. For
this pilot study a prototype instrument was transported
to Ethiopia where it was applied in the outpatient clinic of
Adama Hospital, a referral hospital in Nazareth town, in
the central region of Oromia.
Results
A single breathalyzer test was performed on 60 consent-
ing adults presenting with respiratory problems. Samples
for analysis were collected in disposable collection tubes.
Each individual was shown how to cough into the tube
and requested not to attempt to expectorate sputum.
Each patent coughed at least three times into the device
(short coughs in rapid succession). The procedure was
well tolerated by all participants and the total time taken
for sample collection did not exceed 5 minutes. Sample
collection tubes consisted of two concentric plastic com-
ponents. Once samples had been collected the inner
plunger was depressed and rotated to distribute the sam-
ple on the prism test surface. Tubes were then placed in
the instrument. The initial digital readout was recorded
and the reading observed over a period of two minutes.
Samples that induced a reduction in signal greater than
20 units within two minutes were classified as positive for
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M. tuberculosis antigen; those that did not induce a
reduction of 20 units were classified as negative for M.
tuberculosis antigen. The manufacturer's protocol
instructed that an increase in signal greater than 40 units
be taken to indicate an invalid test; however, such read-
ings were not observed during this study. Patients were
classified according to their clinical presentation, chest
radiography and sputum microscopy.
The mean age was 33.9 yrs (range 17-70) and ratio of
male to female participants 29:31. There was no medical
complaint other than respiratory illness reported by the
patients during the triage; however, one individual was a
known diabetic. All individuals tolerated the breathalyzer
procedure well and a result was obtained for each patient
tested. The time required for the combined nebulization,
sample collection and breathalyzer test did not exceed 10
min, including the time taken to instruct the patient. Pos-
itive breath test results were recorded for 29 (48.3%)
patients. Of 31 patients with a final diagnosis of TB 20
(65%; 95% CI 45-80) were found positive for acid fast
bacilli in their sputum and 23 (74%; 95% CI 55-87)) were
positive for antigen in their breath. When the breath anti-
gen test result was combined with sputum microscopy
29/31 (94%; 95% CI 77-99) of clinically diagnosed TB
patients were detected. The distribution of breathalyzer
results is shown in Table 1. Nine smear negative patients
with a clinical diagnosis of tuberculosis were positive for
antigen in their breath. Six patients provided positive
breathalyzer results that did not correlate with a diagno-
sis of tuberculosis suggesting a specificity of 79% (95% CI
60-91). As shown in Table 2, all six were found negative
for acid fast bacilli in their sputum. Six patients positive
for acid fast bacilli in their sputum were found negative in
the breathalyzer test. A further two patients negative in
both the breath test and by smear microscopy were given
a final diagnosis of tuberculosis, one of whom (P30)
admitted during further investigation that he had previ-
ously received treatment for pulmonary tuberculosis and
was classified as an immunocompromised re-treatment
case. The remaining 23 patients found negative for TB
antigen were diagnosed as having pneumonia (6), bron-
chitis (5), upper respiratory tract infection (5), COPD (4),
congestive heart failure (1), aseptic pneumonia (1) and
echinococcal liver cyst (1).
Discussion
The factors influencing transmission of tuberculosis
amongst individual patients are poorly understood.
Improved understanding of the shedding of Mycobacte-
rium tuberculosis by individual patients would greatly
facilitate efforts to control the disease. We have demon-
strated a novel portable device for assessing TB antigen in
breath. This is the first report of a device that permits
'real time' monitoring of exhaled M. tuberculosis. It is also
the first report of a 'point of care' test that would allow
assessment of individuals in the community whilst they
undertake their normal daily routines. Having demon-
strated that the test can be performed in a clinic with
minimal training further study is now required to deter-
mine the sensitivity of the device when compared to
other markers of infection such as the number of bacilli
in expectorated sputum. At the time of this study smear
microscopy readings in Ethiopia were not graded accord-
ing to the numbers of bacilli observed and further studies
should be undertaken to assess the relationship between
depression of signal in the breathalyzer test and smear
score. Isolation and culture of the bacteria from expecto-
rated sputum remains the most sensitive diagnostic tool
for pulmonary tuberculosis and should necessarily be
included in such studies. The viability of bacteria present
in breath samples should also be ascertained and their
identity confirmed by molecular testing to determine the
specificity of the test. A limitation of this study was that
each patient was subject to a single test. Studies on expec-
torated sputum suggest there is considerable variation in
the number of bacilli present in sequentially collected
sputum and similar variations in the amount of antigen in
cough may occur. To investigate this phenomenon the
breathalyzer test should ideally be performed on multiple
occasions throughout the day. It should also be noted that
the breathalyzer device does not discriminate the size of
the particles detected. Studies of TB transmission indi-
cate that the size of the infected aerosol or particle is crit-
ical to its ability to reach and infiltrate the lung [19,20].
Whereas smaller particles (less than one micron) are not
stable and are quickly dispersed, large droplets of greater
than 5 micron, should they be inhaled are less likely to
reach the alveoli.
The breathalyzer device measures displacement of the
analogue by antigen in the sample and the larger the
Table 1: Results of Breathalyzer test for M. tuberculosis antigen 85B
Diagnosis Breathalyzer test positive Breathalyzer test negative Total
Smear positive TB 14 6 20
Smear negative TB 9 2 11
Not TB 6 23 29
Total 29 31 60
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number of antigens the greater the depression of signal.
However, the absolute signal that the machine displays is
a complex function involving a range of different optical
and biological parameters and the relationship of antigen
concentration to the final readout should be considered
semi quantitative only. The signal displayed is dependant
on both the fluorescent signal from the coating on the
prism and also optical scattering effects. A decrease of
less than 20 units is classed as negative which takes into
account scattering changes if samples 'settle' in position
or evaporation takes place. The cut off value was attained
from unblinded clinical studies undertaken by the test
inventors. The limit of sensitivity of the prototype device
used in this study was not determined but is anticipated
to be in the range of 50-75 colony forming units. Further
studies are required to determine the sensitivity and
specificity of the prism based displacement assay used in
this device, these should include testing other mycobacte-
ria species that may share the Antigen 85 epitopes on
which the displacement assay has been based.
The failure to provide data by the Ethiopian laboratory
contracted to undertake culture of the specimens demon-
strates the fragility of laboratory based diagnostics in
Ethiopia and illustrates the need for simple 'point of care
devices' in such settings. Considerable laboratory infra-
structure is required to undertake culture of M. tubercu-
losis in a controlled and safe environment and such
facilities are rare in Africa. It should also be noted that
although culture would be expected to provide a more
sensitive means of diagnosis the method is slow and
results obtained after a delay of several weeks would be of
limited value in this setting. In this study six smear posi-
tive, presumed TB patients were found negative by the
breathalyzer test. Thus the test may not be considered a
replacement diagnostic test for smear microscopy. How-
ever, when positive data from the two tests were com-
bined 93.5% of patients were identified suggesting the
device might have a role in assisting diagnosis, particu-
larly in those patients unable to expectorate sputum such
as children or the severely immunocompromised. That
TB antigen was not observed in the breath of some smear
positive patients may seem surprising. However, some
evidence to support the finding that bacteria are not con-
stantly exhaled by patients has been provided by Fennelly
and colleagues who, when measuring cultivable cough-
generated aerosols observed that some untreated smear
positive TB cases were negative in their test [13]. That six
patients provided apparent false positive breathalyzer
results that did not correlate with a diagnosis of tubercu-
losis indicates a specificity in the region of 79%. Further
investigation is required to determine the significance of
such results using more sensitive diagnostic technologies
such as culture and nucleic acid amplification tests. An
important consideration for new technology is the cost of
implementation. It is anticipated that should the dispos-
able TB breathalyzer device be produced on a large scale
it would become available for less than USD$5 and that
labor costs would remain modest due to the rapid nature
of the test. The reader is a low cost, portable, multi-use
device that runs on rechargeable batteries and so its cost
can be amortized over several years. Assessment of the
potential benefits of this new technology requires further
study to determine its capabilities either as a tool to
Table 2: False positive and false negative Breathalyzer test results.
Patient Breath test Cough Sputum microscopy CXR report Diagnosis
P9 Positive Bloody Negative Bronchoectasis Pneumonia
P29 Positive Productive Negative Pneumonia Pneumonia
P19 Positive Dry Negative No finding Bronchitis
P31 Positive Productive Negative No finding Bronchitis
P32 Positive Purulent Negative Bronchoectasis COPD
P49 Positive Scanty Negative No finding URTI
P10 Negative Productive Negative Pneumonia Possible PTB
P22 Negative Productive AFB PTB PTB
P29 Negative Purulent AFB PTB PTB
P30 Negative Scanty Negative No finding Re-treatment PTB
P37 Negative Dry AFB No finding PTB
P39 Negative Bloody AFB Pleural effusion PTB
P42 Negative Dry AFB No finding PTB
P53 Negative Bloody AFB Disseminated TB PTB
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screen individuals for exhalation of M. tuberculosis or as
device to aid diagnosis of pulmonary tuberculosis.
Conclusions
The Breathalyzer test shows considerable promise as a
tool to investigate shedding of M. tuberculosis in cough.
Further study is required to determine the sensitivity and
specificity of the test and the relationship of excreted
Ag85B with smear positivity. These preliminary findings
suggest that although this novel testing device cannot
replace sputum microscopy it might assist in the early
identification of TB cases that cannot expectorate spu-
tum for examination. Further study should be undertaken
to assess its value in populations with restricted access to
healthcare and where screening for early tuberculosis dis-
ease using conventional tools is not currently possible.
Methods
The study was approved by the Research Ethics Commit-
tee of the London School of Hygiene & Tropical Medicine
and the Medical Directorate of Adama Hospital. All par-
ticipants provided prior written consent. Patients were
recruited from the outpatients' clinic of Adama Hospital.
The clinic operates a triage system, only those patents
presenting with respiratory complaints were considered
eligible for the study. The triage and breathalyzer test
were performed by separate physicians and results were
not shared to prior to completion of the diagnostic pro-
cess. Demographic and clinical data were recorded to
include sex, age, smoking habits, weight, body tempera-
ture, blood pressure, respiratory rate and description of
cough. All patients were subjected to chest radiogram
and examination of sputum by Ziehl-Nielsen microscopy.
Samples were taken to assess haemoglobin, erythrocyte
sedimentation rate and white blood cell counts. Prior to
testing with the breathalyzer device patients used a nebu-
liser with 0.9% saline to lubricate the trachea using a hand
operated pump (Easy Air Nebuliser Pump, Cameron
Price, Birmingham, UK). To reduce risk of nosocomial
transmission samples were collected in isolation in a ven-
tilated room with the supervising physician using a per-
sonal respirator. Sample collection tubes were single use
and were disposed of following their removal from the
instrument. The breathalyzer test result was not used in
the assessment or management of patients. Facilities to
culture M. tuberculosis were not available at the study
site. Sputum specimens were sent to another laboratory
for investigation by culture on Lowenstein Jensen but no
results were received.
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